血清胃泌素释放肽前体、神经元特异性烯醇化酶在小细胞肺癌患者化疗疗效评价中的应用价值

Value of serum pro-gastrin-releasing peptide and neuron specific enolase in evaluation of chemotherapy efficacy of small cell lung cancer patients

目的探讨血清胃泌素释放肽前体(ProGRP)、神经元特异性烯醇化酶(NSE)在小细胞肺癌(SCLC)患者化疗疗效评价中的应用价值。方法收集100例SCLC患者的临床资料。所有患者均予以化疗,比较化疗前后血清ProGRP、NSE水平,分析ProGRP、NSE与化疗疗效、临床分期及患者预后的关系,绘制受试者工作特征(ROC)曲线,评估ProGRP、NSE在SCLC患者疗效评价中的应用价值。结果化疗前、化疗2个疗程后、化疗4个疗程后,SCLC患者血清ProGRP、NSE水平比较,差异均有统计学意义(P﹤0.01)。不同疗效SCLC患者血清ProGRP、NSE水平比较,差异均有统计学意义(P﹤0.01)。生存患者血清ProGRP、NSE水平均明显低于死亡患者,差异均有统计学意义(P﹤0.01)。局限期SCLC患者ProGRP、NSE水平均明显低于广泛期SCLC患者,差异均有统计学意义(P﹤0.01)。Spearman相关分析显示,化疗4个疗程后ProGRP、NSE水平均与化疗疗效、1年后生存情况、无进展生存期呈负相关(P﹤0.01)。ROC曲线显示,化疗4个疗程后,NSE、ProGRP评价患者化疗疗效的价值均较高。结论血清ProGRP、NSE水平在SCLC患者化疗后降低,可作为SCLC疗效评估、预后预测的标志物。

Objective To investigate the value of serum pro-gastrin-releasing peptide(ProGRP)and neuron specific enolase(NSE)in the evaluation of chemotherapy efficacy in patients with small cell lung cancer(SCLC).Method Clinical data of 100 SCLC patients were collected and all patients received chemotherapy.Serum ProGRP and NSE levels were compared before and after chemotherapy,and the relationship of ProGRP and NSE with chemotherapy efficacy,clinical stage and prognosis was analyzed.Receiver operating characteristic(ROC)curve was drawn to evaluate the efficacy of ProGRP and NSE in evaluating chemotherapy efficacy of SCLC patients.Result There were statistically significant differences in serum ProGRP and NSE levels in SCLC patients before chemotherapy,after 2 courses of chemotherapy and4 courses of chemotherapy(P<0.01).There were statistically significant differences in serum ProGRP and NSE levels among SCLC patients with different therapeutic effects(P<0.01).Serum ProGRP and NSE in survived patients were lower than the death patients(P<0.01).Serum ProGRP and NSE levels in patients with limited stage SCLC were lower than those in patients with extensive stage SCLC(P<0.01).Spearman correlation analysis showed that the levels of ProGRP and NSE after 4 courses of chemotherapy were negatively correlated with chemotherapy efficacy,survival after 1 year,and progression-free survival(PFS)(P<0.01).The ROC curve showed that after 4 courses of chemotherapy,NSE and ProGRP had higher value in evaluating the efficacy of chemotherapy.Conclusion Serum ProGRP and NSE decreases after chemotherapy in patients with SCLC,which can be used as a marker for evaluating efficacy and predicting prognosis of SCLC.